CN104902878A - 含有瑞戈非尼的包衣的药物组合物 - Google Patents

含有瑞戈非尼的包衣的药物组合物 Download PDF

Info

Publication number
CN104902878A
CN104902878A CN201380049461.1A CN201380049461A CN104902878A CN 104902878 A CN104902878 A CN 104902878A CN 201380049461 A CN201380049461 A CN 201380049461A CN 104902878 A CN104902878 A CN 104902878A
Authority
CN
China
Prior art keywords
weight
compositions
coating
pharmaceutical composition
polyvinyl alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380049461.1A
Other languages
English (en)
Chinese (zh)
Inventor
S·思科拉博斯
A·芬克
M·克雷瑟
U·奥伯蒂克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104902878(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Priority to CN202310406916.6A priority Critical patent/CN116392598A/zh
Priority to CN202310409897.2A priority patent/CN116392484A/zh
Priority to CN202010052300.XA priority patent/CN111249247A/zh
Priority to CN202310410047.4A priority patent/CN116392485A/zh
Publication of CN104902878A publication Critical patent/CN104902878A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201380049461.1A 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物 Pending CN104902878A (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202310406916.6A CN116392598A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物
CN202310409897.2A CN116392484A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物
CN202010052300.XA CN111249247A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物
CN202310410047.4A CN116392485A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12183331.3 2012-09-06
EP12183331 2012-09-06
PCT/US2013/058257 WO2014039677A1 (en) 2012-09-06 2013-09-05 Coated pharmaceutical composition containing regorafenib

Related Child Applications (4)

Application Number Title Priority Date Filing Date
CN202310409897.2A Division CN116392484A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物
CN202010052300.XA Division CN111249247A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物
CN202310410047.4A Division CN116392485A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物
CN202310406916.6A Division CN116392598A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物

Publications (1)

Publication Number Publication Date
CN104902878A true CN104902878A (zh) 2015-09-09

Family

ID=46963450

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201380049461.1A Pending CN104902878A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物
CN202310410047.4A Pending CN116392485A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物
CN202310409897.2A Pending CN116392484A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物
CN202310406916.6A Pending CN116392598A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物
CN202010052300.XA Pending CN111249247A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN202310410047.4A Pending CN116392485A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物
CN202310409897.2A Pending CN116392484A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物
CN202310406916.6A Pending CN116392598A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物
CN202010052300.XA Pending CN111249247A (zh) 2012-09-06 2013-09-05 含有瑞戈非尼的包衣的药物组合物

Country Status (43)

Country Link
US (1) US20140065212A1 (https=)
EP (2) EP2892507B1 (https=)
JP (1) JP6445436B2 (https=)
KR (1) KR102162036B1 (https=)
CN (5) CN104902878A (https=)
AP (1) AP2015008292A0 (https=)
AR (1) AR092439A1 (https=)
AU (1) AU2013312531B2 (https=)
BR (1) BR112015004936B1 (https=)
CA (1) CA2883767C (https=)
CL (1) CL2015000544A1 (https=)
CO (1) CO7310528A2 (https=)
CR (1) CR20150114A (https=)
CU (1) CU24244B1 (https=)
CY (1) CY1118839T1 (https=)
DK (1) DK2892507T3 (https=)
EA (1) EA027685B1 (https=)
ES (1) ES2623205T3 (https=)
GT (1) GT201500053A (https=)
HK (1) HK1214170A1 (https=)
HR (1) HRP20170620T1 (https=)
HU (1) HUE032758T2 (https=)
IL (1) IL237350B (https=)
IN (1) IN2015DN01673A (https=)
JO (1) JO3479B1 (https=)
LT (1) LT2892507T (https=)
MA (1) MA37888B1 (https=)
MX (1) MX359922B (https=)
MY (1) MY176135A (https=)
NZ (1) NZ705578A (https=)
PE (1) PE20151005A1 (https=)
PH (1) PH12015500460A1 (https=)
PL (1) PL2892507T3 (https=)
PT (1) PT2892507T (https=)
RS (1) RS56019B1 (https=)
SA (1) SA515360113B1 (https=)
SG (1) SG11201501683WA (https=)
SI (1) SI2892507T1 (https=)
TW (1) TWI640329B (https=)
UA (1) UA115994C2 (https=)
UY (1) UY35006A (https=)
WO (1) WO2014039677A1 (https=)
ZA (1) ZA201501394B (https=)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105136956A (zh) * 2015-09-11 2015-12-09 江苏嘉逸医药有限公司 一种快速测定瑞戈非尼含量的方法
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CN105496975A (zh) * 2015-12-17 2016-04-20 河南润弘制药股份有限公司 一种瑞戈非尼片剂及其制备方法
CN105879049A (zh) * 2016-05-13 2016-08-24 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
CN106880607A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种含有瑞戈非尼的口腔崩解片及其制备方法
CN106880615A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种瑞戈非尼的口服固体制剂及其制备方法
CN106913527A (zh) * 2015-12-28 2017-07-04 江苏先声药业有限公司 一种瑞戈非尼速释微丸及其制备方法
CN107661296A (zh) * 2016-07-27 2018-02-06 江苏先声药业有限公司 一种瑞戈非尼固体分散体及其制备方法
CN110662540A (zh) * 2017-06-02 2020-01-07 拜耳股份公司 用于治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品
CN111053751A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 瑞戈非尼的缓释片剂及其制备方法
CN112367995A (zh) * 2018-07-06 2021-02-12 安吉奥斯医药品有限公司 艾伏尼布形式和药物组合物
CN112584710A (zh) * 2019-06-06 2021-03-30 美国华纳国际生物科技股份有限公司 医药或保健品自乳化固体分散组合物
WO2022148005A1 (zh) * 2021-01-08 2022-07-14 湖南南新制药股份有限公司 一种药物固体分散体及其制备方法
CN115052586A (zh) * 2020-02-07 2022-09-13 拜耳公司 包含瑞戈非尼和稳定剂的药物组合物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
EP3043778B1 (en) * 2013-09-13 2017-09-06 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
CN104586808B (zh) * 2014-12-27 2017-08-18 北京元延医药科技股份有限公司 抗肿瘤药物组合物
CN113018274A (zh) * 2021-03-10 2021-06-25 药源生物科技（启东）有限公司 一种含羟丙甲纤维素的药物组合物及其制备方法
TR2023002707A2 (tr) * 2023-03-10 2024-09-23 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Regorafenib içeren bir farmasötik bileşim.
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026500A1 (en) * 2004-08-27 2006-03-09 Bayer Pharmaceuticals Corporation New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders
WO2007068381A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating inflammatory skin, eye and/or ear diseases
WO2011128261A1 (en) * 2010-04-15 2011-10-20 Bayer Pharma Aktiengesellschaft Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003272504A1 (en) * 2002-09-20 2004-04-08 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
CN1265793C (zh) * 2002-11-18 2006-07-26 杭州容立医药科技有限公司 左西替利嗪伪麻黄碱复方口服制剂及制备方法
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008044111A1 (en) * 2006-10-13 2008-04-17 Pfizer Products Inc. Pharmaceutical formulation tablet
MX2009006037A (es) * 2006-12-07 2009-06-16 Lilly Co Eli Un articulo de manufactura para prasugrel.
JP5351490B2 (ja) * 2007-10-25 2013-11-27 バイエル薬品株式会社 ニフェジピン含有有核錠剤およびその製法
US20140294959A1 (en) * 2011-05-20 2014-10-02 Astrazeneca Uk Limited Pharmaceutical Composition of Rosuvastatin Calcium

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026500A1 (en) * 2004-08-27 2006-03-09 Bayer Pharmaceuticals Corporation New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders
CN101287463A (zh) * 2004-08-27 2008-10-15 拜耳制药公司 用于治疗过度增生性疾病的包含4－(4－(3－(4－氯－3－三氟甲基苯基)－脲基)－3－氟苯氧基)－吡啶－2－羧酸的新药物组合物
WO2007068381A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating inflammatory skin, eye and/or ear diseases
WO2011128261A1 (en) * 2010-04-15 2011-10-20 Bayer Pharma Aktiengesellschaft Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRADLEY J.PRUSAK ET AL: "新型珠光薄膜包衣系统的防潮和薄膜性质的研究", 《中国药科大学学报》 *
崔福德主编: "《药剂学（第二版）》", 31 January 2011, 中国医药科技出版社 *
许芝彬等: "药用薄膜包衣材料的研究新进展", 《中国医药导报》 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CN105136956A (zh) * 2015-09-11 2015-12-09 江苏嘉逸医药有限公司 一种快速测定瑞戈非尼含量的方法
CN106880607A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种含有瑞戈非尼的口腔崩解片及其制备方法
CN106880615A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种瑞戈非尼的口服固体制剂及其制备方法
CN105496975B (zh) * 2015-12-17 2019-01-04 河南润弘制药股份有限公司 一种瑞戈非尼片剂及其制备方法
CN105496975A (zh) * 2015-12-17 2016-04-20 河南润弘制药股份有限公司 一种瑞戈非尼片剂及其制备方法
CN106913527A (zh) * 2015-12-28 2017-07-04 江苏先声药业有限公司 一种瑞戈非尼速释微丸及其制备方法
CN105879049A (zh) * 2016-05-13 2016-08-24 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
CN107661296A (zh) * 2016-07-27 2018-02-06 江苏先声药业有限公司 一种瑞戈非尼固体分散体及其制备方法
CN110662540A (zh) * 2017-06-02 2020-01-07 拜耳股份公司 用于治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品
CN110662540B (zh) * 2017-06-02 2024-01-26 拜耳医药保健有限责任公司 用于治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品
CN112367995A (zh) * 2018-07-06 2021-02-12 安吉奥斯医药品有限公司 艾伏尼布形式和药物组合物
CN111053751A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 瑞戈非尼的缓释片剂及其制备方法
CN112584710A (zh) * 2019-06-06 2021-03-30 美国华纳国际生物科技股份有限公司 医药或保健品自乳化固体分散组合物
CN115052586A (zh) * 2020-02-07 2022-09-13 拜耳公司 包含瑞戈非尼和稳定剂的药物组合物
WO2022148005A1 (zh) * 2021-01-08 2022-07-14 湖南南新制药股份有限公司 一种药物固体分散体及其制备方法

Also Published As

Publication number Publication date
PT2892507T (pt) 2017-05-02
SA515360113B1 (ar) 2016-08-10
BR112015004936A2 (pt) 2017-07-04
CN116392598A (zh) 2023-07-07
ZA201501394B (en) 2016-07-27
UA115994C2 (uk) 2018-01-25
PE20151005A1 (es) 2015-06-27
US20140065212A1 (en) 2014-03-06
PH12015500460B1 (en) 2015-04-20
CU24244B1 (es) 2017-02-02
BR112015004936B1 (pt) 2022-12-06
WO2014039677A1 (en) 2014-03-13
CA2883767C (en) 2018-11-13
TWI640329B (zh) 2018-11-11
SG11201501683WA (en) 2015-04-29
AU2013312531A1 (en) 2015-03-12
EA027685B1 (ru) 2017-08-31
MX2015002815A (es) 2015-05-15
PL2892507T3 (pl) 2017-09-29
CO7310528A2 (es) 2015-06-30
EA201590520A1 (ru) 2015-10-30
HUE032758T2 (en) 2017-10-30
CU20150020A7 (es) 2015-05-28
KR102162036B1 (ko) 2020-10-07
DK2892507T3 (en) 2017-05-01
RS56019B1 (sr) 2017-09-29
MX359922B (es) 2018-10-16
KR20150048872A (ko) 2015-05-07
CN111249247A (zh) 2020-06-09
CY1118839T1 (el) 2018-01-10
CN116392484A (zh) 2023-07-07
AR092439A1 (es) 2015-04-22
AU2013312531B2 (en) 2017-10-19
ES2623205T3 (es) 2017-07-10
SI2892507T1 (sl) 2017-08-31
EP2892507B1 (en) 2017-02-01
CL2015000544A1 (es) 2015-08-21
EP2892507A1 (en) 2015-07-15
JP2015527395A (ja) 2015-09-17
IL237350A0 (en) 2015-04-30
EP3243508A1 (en) 2017-11-15
IN2015DN01673A (https=) 2015-07-03
IL237350B (en) 2020-11-30
LT2892507T (lt) 2017-06-12
JO3479B1 (ar) 2020-07-05
JP6445436B2 (ja) 2018-12-26
MA37888B1 (fr) 2019-08-30
HRP20170620T1 (hr) 2017-06-30
TW201414510A (zh) 2014-04-16
CN116392485A (zh) 2023-07-07
GT201500053A (es) 2015-10-12
MY176135A (en) 2020-07-24
NZ705578A (en) 2017-10-27
CR20150114A (es) 2015-05-11
AP2015008292A0 (en) 2015-02-28
HK1214170A1 (zh) 2016-07-22
MA37888A1 (fr) 2018-07-31
PH12015500460A1 (en) 2015-04-20
UY35006A (es) 2014-03-31
CA2883767A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
CN104902878A (zh) 含有瑞戈非尼的包衣的药物组合物
ES2398564T3 (es) Formulaciones farmacéuticas gastrorresistentes que contienen rifaximina
DK1793824T3 (en) NEW PHARMACEUTICAL COMPOSITIONS COMPRISING 4- (4- (3- (4-chloro-3-trifluoromethylphenyl) ureido) -3-fluoro-phenoxy) -pyridine-2-carboxylic acid to the treatment of hyperproliferative DISORDERS
JP5128948B2 (ja) 癌の治療のための新規な薬剤組成物
US20230075876A1 (en) Pharmaceutical composition containing regorafenib and a stabilizing agent
JPWO2008114859A1 (ja) ピラゾール誘導体を含有する医薬組成物
HK40096791A (zh) 含有瑞戈非尼的包衣的药物组合物
HK40096793A (zh) 含有瑞戈非尼的包衣的药物组合物
HK40096792A (zh) 含有瑞戈非尼的包衣的药物组合物
HK40031894A (en) Coated pharmaceutical composition containing regorafenib
HK40074149A (en) Pharmaceutical composition containing regorafenib and a stabilizing agent

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1214170

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150909

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1214170

Country of ref document: HK